Therapeutic Potential of Induced and Natural FoxP3+ Regulatory T Cells for the Treatment of Graft-Versus-Host Disease
- 352 Downloads
Graft-versus-host disease (GvHD) remains a major complication after allogeneic hematopoietic stem-cell-transplantation. Present GvHD prophylaxis and treatment is still based on unspecific immunosuppressive drug therapy. Over the last decade, the potential of cell-based therapies involving the infusion of regulatory T cells has emerged as a feasible alternative approach for the treatment and prevention of GvHD. Here we review current efforts to translate data obtained in rodent models into clinical trials. Special emphasis is placed on the variety of strategies to generate sufficient numbers of alloantigen-specific regulatory T cells for adoptive cell therapy. This can be achieved either by expansion or by induction of a regulatory phenotype in naive T cells. Stability of the immunosuppressive phenotype of transferred regulatory T cells even in the highly inflammatory environment of acute GvHD will be thereby a critical parameter for actual therapeutic application.
KeywordsGvHD Bone marrow transplantation FoxP3+ regulatory T cells
This work was supported by grants from the Deutsche Forschungsgemeinschaft SFB621-A14 (I. Prinz), KO3582/3-1 (C. Koenecke) and Deutsche Krebshilfe No.109451 (C. Koenecke). We thank Andreas Krueger, Oliver Pabst and Anke Franzke for fruitful discussions and for critically reading the manuscript.
- Deeg HJ, Spitzer TR, Cottler-Fox M et al (1991) Conditioning-related toxicity and acute graft-versus-host disease in patients given methotrexate/cyclosporine prophylaxis. Bone Marrow Transpl 7:193–198Google Scholar
- Hippen KL, Merkel SC, Schirm DK, et al (2011) Massive ex vivo expansion of human natural regulatory T Cells (Tregs) with minimal loss of in vivo functional activity. Sci Transl Med 3:83ra41Google Scholar
- Kroger N, Zabelina T, Kruger W et al (2002) In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors. Bone Marrow Transpl 29:683–689CrossRefGoogle Scholar